Tumor necrosis factor alpha (Tnfα) suppression has been the target for the treatment of IBD, as it is increased locally (intestinal mucosa) and systemically (blood) in IBD patients [4,55]. This evidence concerns the gene TNF and inflammatory bowel disease.